New sealant could cut chest tube time for lung cancer patients
NCT ID NCT07479277
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether applying a surgical sealant (Progel Platinum) to staple lines during lung cancer surgery can reduce the time patients need a chest tube. About 160 adults having minimally invasive lung lobectomy for non-small cell lung cancer will be randomly assigned to get the sealant plus staples or staples alone. The main goal is to see if the sealant shortens chest tube duration and hospital stay.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Progel Platinum surgical sealant
- What this could lead to
- If it works, this could mean fewer days with a chest tube and a shorter hospital stay after lung cancer surgery.
- What could go wrong
- This is a relatively small, early-stage trial. The sealant may not significantly reduce drainage time, and there is a risk of allergic reaction or other complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Azienda Ospedaliera-Universitaria Pisana
NOT_YET_RECRUITINGPisa, Italy
-
Azienda Ospedaliero-Universitaria Careggi
NOT_YET_RECRUITINGFlorence, Italy
-
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
NOT_YET_RECRUITINGMilan, Italy
-
Irccs Ismett
NOT_YET_RECRUITINGPalermo, Italy
-
Ospedale centrale di Bolzano, Chirurgia Toracica e Vascolare
NOT_YET_RECRUITINGBolzano, Italy
-
Unità di Chirurgia Toracica Oncologica
RECRUITINGCandiolo, Torino, 10060, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Can a pill keep lung cancer from returning after surgery?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?